128 related articles for article (PubMed ID: 32118427)
21. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Curtin ML; Pliushchev MA; Li HQ; Torrent M; Dietrich JD; Jakob CG; Zhu H; Zhao H; Wang Y; Ji Z; Clark RF; Sarris KA; Selvaraju S; Shaw B; Algire MA; He Y; Richardson PL; Sweis RF; Sun C; Chiang GG; Michaelides MR
Bioorg Med Chem Lett; 2017 Apr; 27(7):1576-1583. PubMed ID: 28254486
[TBL] [Abstract][Full Text] [Related]
22. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
24. Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP).
Dahl R; Sergienko EA; Su Y; Mostofi YS; Yang L; Simao AM; Narisawa S; Brown B; Mangravita-Novo A; Vicchiarelli M; Smith LH; O'Neill WC; Millán JL; Cosford ND
J Med Chem; 2009 Nov; 52(21):6919-25. PubMed ID: 19821572
[TBL] [Abstract][Full Text] [Related]
25. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract][Full Text] [Related]
26. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety.
Abdel-Maksoud MS; El-Gamal MI; Gamal El-Din MM; Oh CH
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):97-109. PubMed ID: 30362383
[TBL] [Abstract][Full Text] [Related]
28. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
Hartung IV; Hammer S; Hitchcock M; Neuhaus R; Scholz A; Siemeister G; Bohlmann R; Hillig RC; Pühler F
Bioorg Med Chem Lett; 2016 Jan; 26(1):186-93. PubMed ID: 26611920
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
30. Discovery of highly potent human deoxyuridine triphosphatase inhibitors based on the conformation restriction strategy.
Miyahara S; Miyakoshi H; Yokogawa T; Chong KT; Taguchi J; Muto T; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Nomura M; Nagasawa H; Shuto S; Fukuoka M
J Med Chem; 2012 Jun; 55(11):5483-96. PubMed ID: 22607122
[TBL] [Abstract][Full Text] [Related]
31. Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
Hamelin-Morrissette J; Cloutier S; Girouard J; Belgorosky D; Eiján AM; Legault J; Reyes-Moreno C; Bérubé G
Eur J Med Chem; 2015; 96():259-68. PubMed ID: 25890076
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
33. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.
Igoe N; Bayle ED; Fedorov O; Tallant C; Savitsky P; Rogers C; Owen DR; Deb G; Somervaille TC; Andrews DM; Jones N; Cheasty A; Ryder H; Brennan PE; Müller S; Knapp S; Fish PV
J Med Chem; 2017 Jan; 60(2):668-680. PubMed ID: 28068087
[TBL] [Abstract][Full Text] [Related]
34. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors.
Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J
Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.
Jacintho JD; Baccei CS; Bravo Y; Broadhead A; Chen A; Correa L; Fischer K; Laffitte B; Lee C; Lorrain DS; Messmer D; Prasit P; Stebbins KJ; Stock NS
Bioorg Med Chem Lett; 2019 Feb; 29(3):503-508. PubMed ID: 30594433
[TBL] [Abstract][Full Text] [Related]
36. Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
Zagni C; Pistarà V; Oliveira LA; Castilho RM; Romeo G; Chiacchio U; Rescifina A
Eur J Med Chem; 2017 Dec; 141():188-196. PubMed ID: 29031066
[TBL] [Abstract][Full Text] [Related]
37. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
38. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.
Wang X; Bai E; Zhou H; Sha S; Miao H; Qin Y; Liu Z; Wang J; Zhang H; Lei M; Liu J; Hai O; Zhu Y
Bioorg Med Chem; 2019 Feb; 27(3):533-544. PubMed ID: 30606672
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
